Author(s): Maha Kamran,1 Salma Junaid Malik,2 Sadia Hussain,3 Naureena Munawer,4 Amar Akram,5 Ramsha Mushtaq Khan,6 et all
Pages: 30-33 | DOI: https://doi.org/10.5455/pjps.202312010
Background: Valproic acid (VPA) is an anticonvulsant drug used for seizures, bipolar disorder, and migraines. Therapeutic levels range from 50-100 μg/mL, with higher levels causing adverse effects like coagulopathies. VPA can cause thrombocytopenia, platelet dysfunction, acquired von Willebrand disease, and other bleeding disorders. These complications are rarely fatal but are more common in children. This case report examines VPA-induced coagulopathy resulting in mortality in a pediatric burn patient.
Case Presentation: A 16-year-old female with a history of seizures presented with 10% total body surface area superficial partial thickness scald burns to her face, neck and chest. She was started on intravenous VPA for seizure prophylaxis. On hospital day 8 she developed severe gastrointestinal bleeding unresponsive to resuscitation attempts and died due to hemorrhagic shock on day 10. Extensive workup excluded other etiologies like inherited coagulopathies, dengue fever, sepsis, and medications. Falling platelet counts, albumin, lymphocyte and hemoglobin levels were noted with elevated d-dimers, pointing to a VPA-induced bone marrow suppression and platelet dysfunction.
Conclusion: This case demonstrates the potential for fatal bleeding complications with short-term VPA use even at therapeutic doses. It highlights the need for close monitoring of hematologic parameters and maintaining a low threshold for changing anticonvulsant therapy in vulnerable patient populations.
Keywords | Valproic acid, coagulopathy, thrombocytopenia, platelet dysfunction, hemorrhage, burn
1. Lewis JR. Valproic acid (Depakene). A new anticonvul- sant agent. JAMA. 1978;240(20):2190–2
2.Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010:1–18
3.Rupasinghe J, Jasinarachchi M. Progressive encephalo- pathy with cerebral oedema and infarctions associated with valproate and diazepam overdose. J Clin Neurosci. 2011;18(5):710-1
4.Koch-Weser J, Browne TR. Drug therapy: Valproic acid. N Engl J Med. 1980;302(12):661–6
5.Sleiman C, Raffy O, Roué C, Mal H. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest. 2000;117(2):613.
6. Cannizzaro E, Albisetti M, Wohlrab G, Schmugge M. Severe bleeding complications during antiepileptic treatment with valproic acid in children. Neuropedia- trics. 2007;38(1):42–5.
7.Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child. 1982;57(9):681–4.
8.Tanindi S, Akin R, Koseoglu V, Kurekci AE, Gokcay E, Ozcan O. The platelet aggregation in children with epilepsy receiving valproic acid. Thromb Res. 1996; 81 (4):471–6.
9.Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis. 2008;19(5):375–82.
10.Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in chil- dren and adolescents. Rahman A, Mican LM, Fischer C, Campbell AH. Ann Pharmacother. 2009;43:822–830.
11.Köse G, Arhan E, Unal B, Ozaydin E, Guven A, Sayli TR. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol. 2009; 24: 1493–8
12.Zeller JA, Schlesinger S, Runge U, Kessler C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia. 1999;40:186-189
13.Patel AR, Nagalli S. Valproate Toxicity. 2022 Nov 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024:01
14.Choi YH, Lee JH, Shin JJ, Cho YS. A revised risk analy- sis of stress ulcers in burn patients receiving ulcer pro- phylaxis. Clin Exp Emerg Med. 2015 28;2(4):250- 255
All published material becomes the sole property of the Pakistan Journal of Plastic Surgery, copyrighted by the Pakistan Association of Plastic Surgeons (PAPS). By submitting an article or brief communication, all authors agree to these conditions.
During the submission process, all authors have required to complete a copyright transfer agreement, “Author Consent form” By completing the copyright transfer agreement, you are transferring copyright of figures, tables, videos, and the content of the manuscript to the Pakistan Association of Plastic Surgeons (PAPS).
If you do not wish to or cannot transfer copyright of some or all of your content, please contact the editorial office at pjpspakistan@gmail.com.